^
Association details:
| Biomarker: | RHOA L57V |
|---|---|
| Cancer: | Gastric Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors
Published date:
10/30/2020
Excerpt:
...mutation status of TGFBR2, RHOA, and PREX2 influenced the PFS of immunotherapy...RHOA p.L57V, p.L69P, p.D45N mutations had been identified and the median PFS of patients with RHOAwt and RHOAmt were 4.9 months (95%CI, 2.5–7.4 months) and 2.4 months (95%CI, 0.8–4.0 months; p = 0.0056), respectively.
DOI:
10.1186/s12943-020-01274-7
